LABELS · 4b45622d-5003-33a3-e063-6394a90afb6e

Methylprednisolone

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-02-20
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Full extracted label fields

application numbers

NDA011153

boxed warning exact

brand names

Methylprednisolone

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdd233d9-333d-7389-e053-2a95a90a4b42

generic names

METHYLPREDNISOLONE

4b45622d-5003-33a3-e063-6394a90afb6e

indications and usage exact

INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

indications and usage tables exact

is original packager

manufacturer names

NuCare Pharmaceuticals,Inc.

matched search terms

cancer
lymphomas
leukemia

package ndcs

68071-2370-1

product ndcs

68071-2370

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

259966

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 294
end exclusive: true
exact text: INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where appl
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 0

current approval status

not_reconciled

duplicate text group

dup-6f5f44af37cfbd72ce5e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-1f980eead13b2cda1e02

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

end: 62
end exclusive: true
exact text: are indicated
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 49

qualifier mentions

context exact
INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1.
kind
biomarker
polarity
not_inferred
span
end
65
end exclusive
true
exact text
Methylprednisolone tablets are indicated in
label id
4b45622d-5003-33a3-e063-6394a90afb6e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start
22

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 94
end exclusive: true
exact text: INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 577
end exclusive: true
exact text: INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 0

current approval status

not_reconciled

duplicate text group

dup-bc4d37dcf63bb2192426

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-1bb27c91968b6ef63b75

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 377
end exclusive: true
exact text: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 95

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 675
end exclusive: true
exact text: ne or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 178

current approval status

not_reconciled

duplicate text group

dup-a5fe64b40aac32751804

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-77374b76a9c9f268606e

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 475
end exclusive: true
exact text: Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 378

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1131
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 276

current approval status

not_reconciled

duplicate text group

dup-45ade1f29104ae270521

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-6b085000a6e05e827595

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 931
end exclusive: true
exact text: Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 476

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1317
end exclusive: true
exact text: Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe pso
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 732

current approval status

not_reconciled

duplicate text group

dup-3ac1b7255df21df2b84e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-76a8121d93e72c9ee2a3

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1117
end exclusive: true
exact text: Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 932

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1526
end exclusive: true
exact text: arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactio
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 918

current approval status

not_reconciled

duplicate text group

dup-e193d276e3eb2378b440

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-81d4ab1405e8655bffcc

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1326
end exclusive: true
exact text: Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1118

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1800
end exclusive: true
exact text: gic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segmen
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1127

current approval status

not_reconciled

duplicate text group

dup-3663955a0aa0438b0e1d

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-0a3e7f7f1d3acd68457a

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1600
end exclusive: true
exact text: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1327

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2172
end exclusive: true
exact text: tractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate a
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1401

current approval status

not_reconciled

duplicate text group

dup-236655e1dc1607e57906

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-485e6727c6546966d465

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1972
end exclusive: true
exact text: Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1601

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2425
end exclusive: true
exact text: phthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid)
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1773

current approval status

not_reconciled

duplicate text group

dup-11d58801589421b334fc

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-7a9d51464409faf48df4

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2225
end exclusive: true
exact text: Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 1973

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2646
end exclusive: true
exact text: sis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2026

current approval status

not_reconciled

duplicate text group

dup-869b363b712f43644706

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-3e343b1a05cfc6a8b6fe

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

context exact
ematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune)
kind
age
polarity
not_inferred
span
end
2293
end exclusive
true
exact text
adults
label id
4b45622d-5003-33a3-e063-6394a90afb6e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start
2287
context exact
bocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (
kind
age
polarity
not_inferred
span
end
2330
end exclusive
true
exact text
adults
label id
4b45622d-5003-33a3-e063-6394a90afb6e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start
2324

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2446
end exclusive: true
exact text: Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2226

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2762
end exclusive: true
exact text: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases T
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2247

current approval status

not_reconciled

duplicate text group

dup-d7171bbdef2287062387

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-63bd92fcd15c1af7dbaa

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

context exact
es For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
kind
age
polarity
not_inferred
span
end
2530
end exclusive
true
exact text
adults
label id
4b45622d-5003-33a3-e063-6394a90afb6e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start
2524

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2562
end exclusive: true
exact text: Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2447

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2934
end exclusive: true
exact text: anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscella
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2363

current approval status

not_reconciled

duplicate text group

dup-c1a7f4cb9cbd2db2f4be

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-c4b7ff4b1e361ca98bca

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2734
end exclusive: true
exact text: Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2563

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3064
end exclusive: true
exact text: e leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous ch
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2535

current approval status

not_reconciled

duplicate text group

dup-effcd05136d0cf433485

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-87c789bd8988f946966d

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2864
end exclusive: true
exact text: Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2735

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3125
end exclusive: true
exact text: remia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involve
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2665

current approval status

not_reconciled

duplicate text group

dup-5eb4fc3e1d49d1168dd0

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-c08cffec4a292becfca2

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2925
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis 13.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2865

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3130
end exclusive: true
exact text: sus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2726

current approval status

not_reconciled

duplicate text group

dup-6c3985be77cc51684bf4

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-0fa6b70035e36df57e47

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 3075
end exclusive: true
exact text: Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2926

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · unclassified context

application numbers

NDA011153

brand names

Methylprednisolone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3130
end exclusive: true
exact text: tem Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 2876

current approval status

not_reconciled

duplicate text group

dup-2d27a24a27bf12afb196

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE

ind-span-119243a1946f22980bde

label id

4b45622d-5003-33a3-e063-6394a90afb6e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 3130
end exclusive: true
exact text: Trichinosis with neurologic or myocardial involvement.
label id: 4b45622d-5003-33a3-e063-6394a90afb6e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b2bfc8a8b5c4131336b5331cb54aee2ec65b8c7bf57c62520053a56816ba1127
start: 3076

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b45622d-5003-33a3-e063-6394a90afb6e%22

spl effective date

2026-02-20

spl set id

bdd233d9-333d-7389-e053-2a95a90a4b42

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice